Search PubMed⌕ Search

Biomedical subjects

M Nojima

Publications and source records attributed to M Nojima.

72 records · Page 4Linked to original sources
PubMed1986

[A 46, XX true hermaphrodite with H-Y antigen].

A 23-year-old man was admitted to Osaka University Hospital with complaints of breast enlargement and defect of bilateral scrotal content. A gonad-like organ could be palpable at bilateral inguinal area and pubic hair was a female escutcheon in spite of complete male phenotype for both external genitalia and posterior urethra by retrograde urethrogram. Decreased serum value of testosterone and increased the serum value of estradiol and progesterone were found by endocrinological evaluation. Karyotype derived from skin fibroblast and peripheral lymphocyte was 46, XX and H-Y antigen was detected. Exploratory laparotomy disclosed uterus and bilateral ovotestis with epididymis, seminal vesicle and Fallopian tube. The patient received gonadectomy, hysterectomy and insertion of testicular prosthesis.

Adult↗
PubMed1983

[Clinical application of latamoxef during the perinatal period].

Latamoxef (LMOX), a new semisynthetic beta-lactam antibiotic developed by Shionogi Research Laboratory, was evaluated basically and clinically in the perinatal period. In basal study, concentrations of LMOX on maternal serum, umbilical card serum and amniotic fluid were measured by intravenous injection method, and that's placental transferences were relatively favorable. The ratios of umbilical cord serum to maternal serum were 1/3--1/5 at early state after administration, 5--20 minutes, 2/3 at 1.5--1.75 hours. Umbilical serum concentrations were higher than maternal serum concentrations after about 2.5 hours of administration. In 1 case, transferences into tissues of uterus and placenta were studied, that's values were 13.4 and 13.0 micrograms/g at 1.75 hours after administration, respectively. In clinical application, LMOX was administered to 4 cases (intrauterine infection 1 case, urinary tract infection 3 cases) at dose of 2.0 g twice a day by intravenous drip infusion, intravenous injection and intramuscular injection method. Excellent and good clinical response was observed in all 4 cases, and bacteriological response to causative organisms was satisfactory in 3 cases except S. faecalis of mixed infection case. No side effect or abnormal laboratory values were noticed in the all cases.

Adult↗
PubMed1982

Clinical evaluation of a knee-ankle-foot-orthosis for hemiplegic patients.

The KAFO described provides hemiplegics with effective and dynamic ambulation, because of its light weight, easy application, reasonably located genucentric knee and ankle joints, together with the flexibility of thigh and lower leg cuffs and arch support. The flexibility of this orthosis permits proper torsion of thigh and lower leg cuff. After application of the KAFO, hemiplegics become able to extend or flex their hip or knee joints in a wide range of motion. As the result of these characteristics, hemiplegics can ambulate smoothly and effectively in the KAFO as described in the results and practical investigations.

Adult↗
PubMed1981

An aberrant adenylate kinase isoenzyme from the serum of patients with Duchenne muscular dystrophy.

The sera from patients with human Duchenne (X-linked) progressive muscular dystrophy contain elevated adenylate kinase (ATP: AMP phosphotransferase, EC 2.7.4.3) activities, in addition to their characteristically high creatine kinase (ATP; creatine N-phosphotransferase, EC 2.7.3.2) activities. By agarose gel electrophoresis of human Duchenne dystrophic serum, the presence of an apparently normal human serum adenylate kinase together with a variant species of adenylate kinase was detected. The latter enzyme species appeared, in its mobility, to be similar to that of the normal human liver-type adenylate kinase. The presence of this aberrant liver-type adenylate kinase could also be demonstrated by characteristic (for the liver type) inhibition patterns with P1,P5-di-(adenosine-5')pentaphosphate, 5,5'-dithiobis(2-nitrobenzoate) and phosphoenolpyruvate. On the other hand, by inhibition titrations with an anti-muscle-type adenylate kinase, hemolysates from the erythrocytes of several Duchenne and Becker's dystrophics were found to contain approx. 96% muscle-type adenylate kinase and their serum approx. 97% muscle-type adenylate kinase. These same patients contained approx. 89% M-M type creatine kinase in their serum (by inhibition against anti-human muscle-type creatine kinase) indicative of the presence also of M-B plus B-B type active isoenzymes. All of these data can best be explained by the presence of a variant or mutant adenylate kinase isoenzyme in the dystrophic serum. This isoenzyme appears to resemble the liver type in its inhibition patterns with P1,P5-di(adenosine-5')pentaphosphate, 5,5'-dithiobis(2-nitrobenzoate) and phosphoenolpyruvate, and in its heat stability (compare also the agarose gel electrophoresis pattern); but structurally, it is a muscle type, or derived from a muscle type, as shown immunologically by inhibition reactions with anti-muscle-type adenylate kinase. Whether this is a fetal-type isoenzyme of adenylate kinase will require further investigation.

Adenine Nucleotides↗